Cash flow Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
96.31 ^USD	-1.05%		-1.21%	+20.92%

02-11	Revolution Medicines, Inc. Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026, Feb-11-2026 09:30 AM
01-29	Revolution Medicines Says First Patient Dosed in Solid Tumor Trial	MT

3ffb6f03a30b7d.TXICCGj7B-qYhJrZ4T5GCqLJuzgSL1cJeg0FPX3amng.fho7Q1vPYazwsP--lH8vXJGz91ZGVzZBKVxdcTii0wEfBjVNUbIwx_LN6Q

Published financial data: REVOLUTION MEDICINES, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2020	2021	2022	2023	2024
Revenues	42.98M	29.39M	35.38M	11.58M	-
Total Revenues	42.98M	29.39M	35.38M	11.58M	-
Cost of Goods Sold, Total	132M	187M	253M	411M	592M
Gross Profit	-89.27M	-158M	-218M	-400M	-592M
Selling General & Admin Expenses, Total	21.43M	30.45M	40.59M	62.02M	97.3M
Other Operating Expenses, Total	21.43M	30.45M	40.59M	62.02M	97.3M
Operating Income	-111M	-188M	-258M	-462M	-690M
Interest Expense, Total	-71K	-12K	-	-303K	-
Interest And Investment Income	2.24M	929K	9.15M	47.48M	86.88M
Net Interest Expenses	2.17M	917K	9.15M	47.18M	86.88M
Other Non Operating Income (Expenses)	-	-	-	115K	1.8M
EBT, Excl. Unusual Items	-109M	-187M	-249M	-414M	-601M
Merger & Related Restructuring Charges	-	-	-	-25.5M	-
EBT, Incl. Unusual Items	-109M	-187M	-249M	-440M	-601M
Income Tax Expense	-371K	-	-420K	-3.52M	-753K
Earnings From Continuing Operations	-108M	-187M	-249M	-436M	-600M
Net Income to Company	-108M	-187M	-249M	-436M	-600M
Net Income - (IS)	-108M	-187M	-249M	-436M	-600M
Preferred Dividend and Other Adjustments	2.22M	-	-	-	-
Net Income to Common Incl Extra Items	-110M	-187M	-249M	-436M	-600M
Net Income to Common Excl. Extra Items	-110M	-187M	-249M	-436M	-600M
Per Share Items
Net EPS - Basic	-2.01	-2.57	-3.08	-3.86	-3.58
Basic EPS - Continuing Operations	-2.01	-2.57	-3.08	-3.86	-3.58
Basic Weighted Average Shares Outstanding	54.87M	72.81M	80.63M	113M	168M
Net EPS - Diluted	-2.01	-2.57	-3.08	-3.86	-3.58
Diluted EPS - Continuing Operations	-2.01	-2.57	-3.08	-3.86	-3.58
Diluted Weighted Average Shares Outstanding	54.87M	72.81M	80.63M	113M	168M
Normalized Basic EPS	-1.24	-1.61	-1.93	-2.29	-2.24
Normalized Diluted EPS	-1.24	-1.61	-1.93	-2.29	-2.24
Supplemental Items
EBITDA	-108M	-185M	-254M	-457M	-683M
EBITA	-111M	-188M	-258M	-462M	-690M
EBIT	-111M	-188M	-258M	-462M	-690M
EBITDAR	-105M	-182M	-248M	-448M	-671M
Total Revenues (As Reported)	42.98M	29.39M	35.38M	11.58M	-
Effective Tax Rate - (Ratio)	0.34	-	0.17	0.8	0.13
Current Domestic Taxes	-	-	-	112K	27K
Current Foreign Taxes	-	-	-	212K	-42K
Total Current Taxes	-	-	-	324K	-15K
Deferred Domestic Taxes	-	-	-419K	-3.86M	-721K
Deferred Foreign Taxes	-	-	-	17K	-17K
Total Deferred Taxes	-371K	-	-419K	-3.85M	-738K
Normalized Net Income	-67.83M	-117M	-156M	-259M	-376M
Supplemental Operating Expense Items
General and Administrative Expenses	21.43M	30.45M	40.59M	62.02M	97.3M
Research And Development Expense From Footnotes	132M	187M	253M	423M	592M
Net Rental Expense, Total	2.7M	3.4M	6.4M	8.18M	11.6M
Imputed Operating Lease Interest Expense	93.27K	6.56K	-	261K	-
Imputed Operating Lease Depreciation	2.61M	3.39M	-	7.92M	-
Stock-Based Comp., COGS (Total)	4.85M	11.85M	18.11M	34.13M	50.97M
Stock-Based Comp., G&A Exp. (Total)	4.04M	8.88M	13.08M	27.65M	28.22M
Total Stock-Based Compensation	8.89M	20.72M	31.2M	61.77M	79.2M

Fiscal Period: December	2020	2021	2022	2023	2024
Assets
Cash And Equivalents	104M	108M	161M	696M	543M
Short Term Investments	336M	469M	484M	1.16B	1.75B
Total Cash And Short Term Investments	441M	577M	645M	1.85B	2.29B
Accounts Receivable, Total	6.39M	5.93M	4.67M	1.25M	-
Total Receivables	6.39M	5.93M	4.67M	1.25M	-
Prepaid Expenses	3.83M	6.79M	10.57M	25.07M	38.33M
Other Current Assets, Total	3.16M	-	-	-	-
Total Current Assets	454M	590M	660M	1.88B	2.33B
Gross Property Plant And Equipment	47.27M	82.05M	88.22M	118M	164M
Accumulated Depreciation	-10.94M	-10.81M	-14.49M	-17.69M	-21.82M
Net Property Plant And Equipment	36.34M	71.24M	73.74M	100M	142M
Goodwill	14.61M	14.61M	14.61M	14.61M	14.61M
Other Intangibles, Total	60.94M	59.88M	58.81M	57.74M	56.67M
Deferred Charges Long-Term	-	500K	600K	-	-
Other Long-Term Assets, Total	1.39M	2M	3.99M	10.06M	17.57M
Total Assets	567M	738M	812M	2.06B	2.56B
Liabilities
Accounts Payable, Total	12.61M	14.06M	21.31M	61.79M	54.43M
Accrued Expenses, Total	18.69M	27.41M	28.94M	70.8M	96.03M
Current Portion of Leases	3.69M	6.21M	6.77M	7.37M	12.87M
Unearned Revenue Current, Total	12.11M	12.36M	4.46M	-	-
Other Current Liabilities	78K	311K	505K	3.9M	583K
Total Current Liabilities	47.18M	60.35M	61.98M	144M	164M
Long-Term Leases	28.99M	60.42M	57.43M	80.58M	123M
Unearned Revenue Non Current	8.48M	6.57M	-	-	-
Deferred Tax Liability Non Current	7.44M	7.44M	7.02M	3.12M	2.35M
Other Non Current Liabilities	632K	634K	301K	7.97M	3.86M
Total Liabilities	92.72M	135M	127M	236M	293M
Preferred Stock Convertible	-	-	-	-	-
Total Preferred Equity	-	-	-	-	-
Common Stock, Total	7K	8K	9K	16K	18K
Additional Paid In Capital	740M	1.06B	1.39B	2.96B	4B
Retained Earnings	-266M	-453M	-701M	-1.14B	-1.74B
Comprehensive Income and Other	116K	-376K	-1.78M	544K	1.32M
Total Common Equity	475M	603M	685M	1.83B	2.27B
Total Equity	475M	603M	685M	1.83B	2.27B
Total Liabilities And Equity	567M	738M	812M	2.06B	2.56B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	73.38M	74.19M	90.49M	165M	186M
ECS Total Common Shares Outstanding	66.6M	74.14M	90.41M	165M	186M
Book Value / Share	7.13	8.13	7.58	11.09	12.19
Tangible Book Value	399M	528M	612M	1.75B	2.19B
Tangible Book Value Per Share	5.99	7.12	6.77	10.65	11.8
Total Debt	32.68M	66.63M	64.2M	87.94M	136M
Net Debt	-408M	-510M	-581M	-1.77B	-2.15B
Debt Equivalent Oper. Leases	21.6M	27.2M	51.2M	65.46M	92.84M
Account Code - Inventory Valuation	3	3	-	3	3
Machinery, Total	11.6M	14.98M	21.74M	28.09M	31.44M
Full Time Employees	125	188	246	378	534

Fiscal Period: December	2020	2021	2022	2023	2024
Net Income	-108M	-187M	-249M	-436M	-600M
Depreciation & Amortization - CF	5.48M	6.26M	8.59M	8.24M	10.76M
Amortization of Goodwill and Intangible Assets - (CF)	-32K	-31K	-31K	-32K	-31K
Depreciation & Amortization, Total	5.44M	6.23M	8.56M	8.21M	10.72M
Amortization of Deferred Charges, Total - (CF)	1.1M	1.1M	1.1M	1.1M	1.1M
(Gain) Loss From Sale Of Asset	-	119K	19K	52K	118K
(Gain) Loss on Sale of Investments - (CF)	968K	3.01M	-3.08M	-22.2M	-44.56M
Stock-Based Compensation (CF)	8.89M	20.72M	31.2M	61.77M	79.2M
Other Operating Activities, Total	-	-	-	115K	-4.32M
Change In Accounts Receivable	2.34M	464K	1.26M	3.42M	1.25M
Change In Accounts Payable	305K	2.24M	7.29M	32.47M	-6.46M
Change in Unearned Revenues	-11.26M	-1.66M	-14.47M	-4.46M	-
Change In Deferred Taxes	-375K	-	-419K	-3.91M	-762K
Change in Other Net Operating Assets	681K	7.68M	-7.14M	9.23M	6.38M
Cash from Operations	-100M	-147M	-224M	-351M	-557M
Capital Expenditure	-2.93M	-6.53M	-10.82M	-7.73M	-10.31M
Sale of Property, Plant, and Equipment	-	-	-	-	-
Cash Acquisitions	-	-	-	-	-
Sale (Purchase) of Intangible assets	-	-	-	-	-
Investment in Marketable and Equity Securities, Total	-231M	-136M	-13.3M	-335M	-544M
Cash from Investing	-234M	-142M	-24.12M	-343M	-554M
Issuance of Common Stock	423M	295M	301M	392M	864M
Repurchase of Common Stock	-	-	-	-4.03M	-
Issuance of Preferred Stock	-	-	-	-	-
Other Financing Activities, Total	-	-424K	42K	841M	95.71M
Cash from Financing	423M	294M	301M	1.23B	959M
Net Change in Cash	88.48M	4.88M	52.92M	536M	-152M
Supplemental Items
Levered Free Cash Flow	-58.26M	-84.69M	-133M	-155M	-348M
Unlevered Free Cash Flow	-58.21M	-84.68M	-133M	-155M	-348M
Change In Net Working Capital	1.52M	-11.29M	1.45M	-70.19M	-2.55M

Fiscal Period: December	2020	2021	2022	2023	2024
Profitability
Return on Assets	-17.56	-18	-20.83	-20.08	-18.66
Return on Total Capital	-20.96	-19.97	-22.76	-21.67	-19.97
Return On Equity %	-34.49	-34.74	-38.63	-34.75	-29.33
Return on Common Equity	-68.54	-34.74	-38.63	-34.75	-29.33
Margin Analysis
Gross Profit Margin %	-207.68	-536.09	-615.3	-3.45K	-
SG&A Margin	49.85	103.61	114.71	535.59	-
EBITDA Margin %	-251.54	-629.32	-718.88	-3.94K	-
EBITA Margin %	-257.61	-639.81	-730.1	-3.99K	-
EBIT Margin %	-257.54	-639.7	-730.01	-3.99K	-
Income From Continuing Operations Margin %	-251.63	-636.58	-702.95	-3.77K	-
Net Income Margin %	-251.63	-636.58	-702.95	-3.77K	-
Net Avail. For Common Margin %	-256.79	-636.58	-702.95	-3.77K	-
Normalized Net Income Margin	-157.81	-397.86	-440.09	-2.24K	-
Levered Free Cash Flow Margin	-135.53	-288.16	-375.46	-1.34K	-
Unlevered Free Cash Flow Margin	-135.43	-288.14	-375.46	-1.34K	-
Asset Turnover
Asset Turnover	0.11	0.05	0.05	0.01	-
Fixed Assets Turnover	1.98	0.55	0.49	0.13	-
Receivables Turnover (Average Receivables)	5.68	4.77	6.67	3.91	-
Short Term Liquidity
Current Ratio	9.63	9.77	10.65	13.06	14.2
Quick Ratio	9.48	9.66	10.48	12.89	13.97
Operating Cash Flow to Current Liabilities	-2.12	-2.44	-3.62	-2.44	-3.4
Days Sales Outstanding (Average Receivables)	64.42	76.51	54.69	93.41	-
Average Days Payable Outstanding	33.22	26.03	25.5	36.87	35.91
Long Term Solvency
Total Debt/Equity	6.89	11.06	9.37	4.82	6
Total Debt / Total Capital	6.44	9.96	8.57	4.59	5.66
LT Debt/Equity	6.11	10.03	8.38	4.41	5.43
Long-Term Debt / Total Capital	5.71	9.03	7.66	4.21	5.12
Total Liabilities / Total Assets	16.34	18.35	15.61	11.42	11.46
EBIT / Interest Expense	-1.56K	-15.67K	-	-1.52K	-
EBITDA / Interest Expense	-1.48K	-15.13K	-	-1.48K	-
(EBITDA - Capex) / Interest Expense	-1.53K	-15.67K	-	-1.51K	-
Total Debt / EBITDA	-0.31	-0.37	-0.26	-0.2	-0.2
Net Debt / EBITDA	3.87	2.81	2.34	3.94	3.21
Total Debt / (EBITDA - Capex)	-0.3	-0.35	-0.25	-0.19	-0.2
Net Debt / (EBITDA - Capex)	3.77	2.71	2.24	3.87	3.16
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-14.1	-31.62	20.38	-67.27	-
Gross Profit, 1 Yr. Growth %	114	76.5	38.17	83.59	48.18
EBITDA, 1 Yr. Growth %	108.41	71.07	37.51	79.55	49.56
EBITA, 1 Yr. Growth %	104.48	69.82	37.37	78.75	49.35
EBIT, 1 Yr. Growth %	104.54	69.84	37.38	78.75	49.35
Earnings From Cont. Operations, 1 Yr. Growth %	126.92	72.98	32.93	75.46	37.52
Net Income, 1 Yr. Growth %	126.92	72.98	32.93	75.46	37.52
Normalized Net Income, 1 Yr. Growth %	108.56	72.39	33.16	66.34	44.99
Diluted EPS Before Extra, 1 Yr. Growth %	-90.99	27.75	20.04	25.02	-7.23
Accounts Receivable, 1 Yr. Growth %	-26.83	-7.26	-21.18	-73.16	-
Net Property, Plant and Equip., 1 Yr. Growth %	408.42	96.04	3.51	35.64	41.8
Total Assets, 1 Yr. Growth %	157.29	30.06	10.02	153.93	24.09
Tangible Book Value, 1 Yr. Growth %	-274.14	32.31	15.85	186.68	25.09
Common Equity, 1 Yr. Growth %	-411.11	26.94	13.71	166.52	24.04
Cash From Operations, 1 Yr. Growth %	101.68	47.09	52.47	56.23	59.01
Capital Expenditures, 1 Yr. Growth %	13.29	122.57	65.69	-28.54	33.37
Levered Free Cash Flow, 1 Yr. Growth %	743.3	45.42	56.85	16.84	124.02
Unlevered Free Cash Flow, 1 Yr. Growth %	750.81	45.52	56.86	16.7	124.29
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	46	-23.36	-9.27	-37.23	-
Gross Profit, 2 Yr. CAGR %	69.92	94.35	56.16	59.27	64.94
EBITDA, 2 Yr. CAGR %	67.87	88.82	53.38	57.13	63.87
EBITA, 2 Yr. CAGR %	66.52	86.35	52.74	56.7	63.39
EBIT, 2 Yr. CAGR %	66.5	86.38	52.75	56.71	63.39
Earnings From Cont. Operations, 2 Yr. CAGR %	60.88	98.12	51.64	52.72	55.33
Net Income, 2 Yr. CAGR %	60.88	98.12	51.64	52.72	55.33
Normalized Net Income, 2 Yr. CAGR %	61.93	89.61	51.51	48.83	55.3
Diluted EPS Before Extra, 2 Yr. CAGR %	-69.22	-66.07	23.84	22.51	7.69
Accounts Receivable, 2 Yr. CAGR %	-6.44	-17.62	-14.5	-54.01	-
Net Property, Plant and Equip., 2 Yr. CAGR %	129.95	215.71	42.45	18.49	38.69
Total Assets, 2 Yr. CAGR %	82.38	82.93	19.62	67.14	77.51
Tangible Book Value, 2 Yr. CAGR %	46.44	51.79	23.81	82.24	89.37
Common Equity, 2 Yr. CAGR %	109.24	98.73	20.15	74.09	81.82
Cash From Operations, 2 Yr. CAGR %	808.26	72.23	49.75	54.33	57.61
Capital Expenditures, 2 Yr. CAGR %	39.88	58.79	92.03	8.81	-2.38
Levered Free Cash Flow, 2 Yr. CAGR %	87.43	250.13	51.03	35.37	61.78
Unlevered Free Cash Flow, 2 Yr. CAGR %	87.76	251.81	51.08	35.3	61.78
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-	13.38	-10.91	-35.41	-
Gross Profit, 3 Yr. CAGR %	49.74	72.08	73.46	64.82	55.48
EBITDA, 3 Yr. CAGR %	53.42	68.93	69.88	61.65	54.57
EBITA, 3 Yr. CAGR %	52.65	67.61	68.34	60.96	54.21
EBIT, 3 Yr. CAGR %	52.64	67.61	68.36	60.97	54.21
Earnings From Cont. Operations, 3 Yr. CAGR %	51.46	64.82	73.45	59.2	47.48
Net Income, 3 Yr. CAGR %	51.46	64.82	73.45	59.2	47.48
Normalized Net Income, 3 Yr. CAGR %	51.64	65.34	68.54	56.3	47.54
Diluted EPS Before Extra, 3 Yr. CAGR %	-53.68	-50.54	-48.3	24.23	11.66
Accounts Receivable, 3 Yr. CAGR %	-	-6.71	-18.83	-41.9	-
Net Property, Plant and Equip., 3 Yr. CAGR %	90.54	118.04	117.7	40.14	25.8
Total Assets, 3 Yr. CAGR %	235.11	62.94	54.41	53.74	51.34
Tangible Book Value, 3 Yr. CAGR %	80.64	41.57	38.72	63.79	60.76
Common Equity, 3 Yr. CAGR %	91.38	77.13	64.98	56.69	55.49
Cash From Operations, 3 Yr. CAGR %	58.46	395.07	65.37	51.88	55.88
Capital Expenditures, 3 Yr. CAGR %	23.03	63.3	61.06	38.12	16.45
Levered Free Cash Flow, 3 Yr. CAGR %	-	72.21	167.91	38.64	60.12
Unlevered Free Cash Flow, 3 Yr. CAGR %	-	72.45	168.77	38.62	60.13
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-	-	-	-10.5	-
Gross Profit, 5 Yr. CAGR %	-	-	52.28	66.84	70
EBITDA, 5 Yr. CAGR %	-	-	53.4	64.11	67.45
EBITA, 5 Yr. CAGR %	-	-	52.68	63.16	66.34
EBIT, 5 Yr. CAGR %	-	-	52.68	63.16	66.36
Earnings From Cont. Operations, 5 Yr. CAGR %	-	-	51.53	59.87	65.96
Net Income, 5 Yr. CAGR %	-	-	51.53	59.87	65.96
Normalized Net Income, 5 Yr. CAGR %	-	-	51.58	58.53	63.11
Diluted EPS Before Extra, 5 Yr. CAGR %	-	-	-31.36	-28.91	-30.66
Accounts Receivable, 5 Yr. CAGR %	-	-	-	-29.7	-
Net Property, Plant and Equip., 5 Yr. CAGR %	-	-	69.61	70.84	81.77
Total Assets, 5 Yr. CAGR %	-	-	121.94	64.61	63.27
Tangible Book Value, 5 Yr. CAGR %	-	-	55.3	56.62	57.11
Common Equity, 5 Yr. CAGR %	-	-	58.86	75.91	71.52
Cash From Operations, 5 Yr. CAGR %	-	-	54.92	210.59	62.22
Capital Expenditures, 5 Yr. CAGR %	-	-	47.01	38.82	31.83
Levered Free Cash Flow, 5 Yr. CAGR %	-	-	-	56.4	118.96
Unlevered Free Cash Flow, 5 Yr. CAGR %	-	-	-	56.5	119.38